Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II ...

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...

Albany College of Pharmacy and Health Sciences’ Professor Tom Lodise will lead a study on complicated urinary tract infections (cUTI's) caused by enterobacterales, a type of bacteria.

Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II clinical trial (RCT), offering an early signal that could reshape how advanced ...

Hospital rooms and ambulances aren’t the only places to find intravenous hookups in Tucson anymore. Instead, for your next fluid drip, think IV lounges with reclining chairs or even a refurbished van.

Therapeutic drug monitoring would seem like an obvious match with rheumatology. Patients with clinically challenging ...

This study was a retrospective observational analysis using the PurpleLab ® CLEAR Claims database, a comprehensive dataset based on medical insurance claims across the United States and was conducted ...

Life-saving treatments for children with orphan illnesses often move slowly, if at all, through the federal approval process.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...

Declan O’Brien had a unique overview of one of the fastest-growing areas within medical therapy – intravenous foods and medicines for the treatment of complex diseases such as cancer. O’Brien was at ...

A respiratory virus has been spreading in several states that isn’t the flu or a cold.

Lykke Vestergaard Kastbjerg, 42, and her father Niels, 73, are among hundreds travelling to the UK for treatment.